In vitro antifungal susceptibility testing of clinical isolates of Aspergillus flavus against tree triazoles

Ref ID: 19565

Author:

H Badali1, S Rezaie2, F Aala3, M Gerami Shoar2, S Khodavaisy2,3*

Author address:

1Department of Medical Mycology and Parasitology /Invasive Fungi Research Centre (IFRC), School of
Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2Department of Medical Mycology and Parasitology, Tehran University of Medical Scienc

Full conference title:

6th Advances Against Aspergillosis 2014

Abstract:

Purpose:
Aspergillus flavus is the second leading cause of invasive and non-invasive aspergillosis. The
occurrence of A. flavus is worldwide especially in tropical and subtropical regions. The vital
importance of A. flavus has been grown in the last years. Presently appearance of resistance to
antifungal agents among Aspergillus species is dramatically increasing. Therefore, in the present
study, we evaluated the in vitro activity of three antifungal agents against A. flavus isolated from
different sources.
Methods:
In total, 50 strains of A. flavus which have been isolated from various specimens (nail, bronchoalveolar
lavage, paranasal sinus) from suspected patients of aspergillosis patients. All strains were identified
based on conventional methods and subsequently confirmed by DNA sequencing of the β -tubulin
gene. The minimal inhibitory concentrations (MIC) of itraconazole, voriconazole, and posaconazole
were determined using the broth microdilution method in accordance with the guidelines of Clinical
and Laboratory Standards Institute (CLSI) document M38-A2.
Results:
The resulting MIC90 s for all A. flavus strains was in increasing order, as follows: posaconazole
(0.25 μg/ml); voriconazole (0.5 μg/ml) and itraconazole (0.75 μg/ml). The results showed that the
activity of posaconazole was significantly higher than other tested azole agents.
Discussion:
The present study based on in vitro activity showed that posaconazole followed by voriconazole might
have a potent activity with a best choice of alternative to previous antifungal drugs, for aspergillosis
and confirmed that the resistance of Aspergillus species to other agents, and are contradictory to cure
rates achieved by patients who have used it to treat aspergillosis. However, clinical effectiveness of
new generations remains to be determined.

Abstract Number: 92

Conference Year: 2014

Link to conference website: http://www.AAA2014.org

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster